Cargando…
Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma
BACKGROUND: A frequent mechanism of acquired multidrug resistance in human cancers is overexpression of ATP-binding cassette transporters such as the Multi-Drug Resistance Protein 1 (MDR-1). Nutlin-3, an MDM2–p53 antagonist, has previously been reported to be a competitive MDR-1 inhibitor. METHODS:...
Autores principales: | Chen, L, Zhao, Y, Halliday, G C, Berry, P, Rousseau, R F, Middleton, S A, Nichols, G L, Del Bello, F, Piergentili, A, Newell, D R, Lunec, J, Tweddle, D A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134492/ https://www.ncbi.nlm.nih.gov/pubmed/24921920 http://dx.doi.org/10.1038/bjc.2014.325 |
Ejemplares similares
-
Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma
por: Chen, Lindi, et al.
Publicado: (2015) -
MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63
por: Gamble, Laura D., et al.
Publicado: (2011) -
Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma
por: Wu, Chiao-En, et al.
Publicado: (2018) -
Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma
por: Chen, Lindi, et al.
Publicado: (2019) -
Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925
por: Yang, X, et al.
Publicado: (2014)